Business Description
ISIN : US7140461093
Total Employee Number:
11,000Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.31 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.46 | |||||
Debt-to-EBITDA | 4.52 | |||||
Interest Coverage | 5.44 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.9 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.2 | |||||
3-Year EBITDA Growth Rate | -11.1 | |||||
3-Year EPS without NRI Growth Rate | -9.9 | |||||
3-Year FCF Growth Rate | -2.4 | |||||
3-Year Book Growth Rate | 3.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.83 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.08 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.08 | |||||
9-Day RSI | 72.2 | |||||
14-Day RSI | 68.51 | |||||
3-1 Month Momentum % | 14.09 | |||||
6-1 Month Momentum % | 11.57 | |||||
12-1 Month Momentum % | 21.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.8 | |||||
Quick Ratio | 1.5 | |||||
Cash Ratio | 0.8 | |||||
Days Inventory | 106.57 | |||||
Days Sales Outstanding | 87.41 | |||||
Days Payable | 48.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.22 | |||||
Dividend Payout Ratio | 0.05 | |||||
Forward Dividend Yield % | 0.22 | |||||
5-Year Yield-on-Cost % | 0.22 | |||||
3-Year Average Share Buyback Ratio | 3.8 | |||||
Shareholder Yield % | 3.38 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.98 | |||||
Operating Margin % | 12.27 | |||||
Net Margin % | 8.16 | |||||
EBITDA Margin % | 25.37 | |||||
FCF Margin % | 19.17 | |||||
OCF Margin % | 21.55 | |||||
ROE % | 3.25 | |||||
ROA % | 1.96 | |||||
ROIC % | 3.08 | |||||
3-Year ROIIC % | 11.35 | |||||
ROC (Joel Greenblatt) % | 26.53 | |||||
ROCE % | 2.97 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 60.17 | |||||
Forward PE Ratio | 23.63 | |||||
PE Ratio without NRI | 23.62 | |||||
Shiller PE Ratio | 27.75 | |||||
Price-to-Owner-Earnings | 28.48 | |||||
PS Ratio | 4.9 | |||||
PB Ratio | 1.95 | |||||
Price-to-Free-Cash-Flow | 25.57 | |||||
Price-to-Operating-Cash-Flow | 22.74 | |||||
EV-to-EBIT | 50.28 | |||||
EV-to-Forward-EBIT | 31.94 | |||||
EV-to-EBITDA | 22.22 | |||||
EV-to-Forward-EBITDA | 18.49 | |||||
EV-to-Revenue | 5.64 | |||||
EV-to-Forward-Revenue | 5.66 | |||||
EV-to-FCF | 29.42 | |||||
Price-to-GF-Value | 1.07 | |||||
Price-to-Projected-FCF | 1.18 | |||||
Price-to-Median-PS-Value | 1.18 | |||||
Earnings Yield (Greenblatt) % | 1.99 | |||||
FCF Yield % | 3.96 | |||||
Forward Rate of Return (Yacktman) % | -12.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:RVTY
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Revvity Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,911.811 | ||
| EPS (TTM) ($) | 2.1 | ||
| Beta | 1.1729 | ||
| 3-Year Sharpe Ratio | -0.04 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 33.25 | ||
| 14-Day RSI | 68.51 | ||
| 14-Day ATR ($) | 3.850219 | ||
| 20-Day SMA ($) | 117.65 | ||
| 12-1 Month Momentum % | 21.09 | ||
| 52-Week Range ($) | 81.22 - 126.9 | ||
| Shares Outstanding (Mil) | 111.59 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Revvity Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Revvity Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-24 | In 181 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-02 08:00 | In 160 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-02 | In 159 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-27 08:00 | In 62 days | ||
| Third quarter earnings results for 2026 | 2026-10-27 | In 61 days | ||
| USD 0.070000 Cash Dividend | 2026-10-23 | In 57 days | ||
| Guidance call for 2026 | 2026-09-15 09:05 | In 20 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-14 08:30 | In 19 days | ||
| Wells Fargo 21st Annual Healthcare Conference | 2026-09-09 08:45 | In 14 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 07:30 | 115.22 (+2.44%) |
Revvity Inc Frequently Asked Questions
Guru Commentaries on NYSE:RVTY
Revvity Inc. is a global life sciences company that has shifted its innovation focus to faster growing areas such as cell and gene therapy, proteins, genomics, and biologics. This strategic pivot positions Revvity to capitalize on emerging trends in the life sciences sector, enhancing its growth potential. As a recent spinoff of PerkinElmer Inc., Revvity is well-placed to leverage its legacy while expanding its research solutions to a broad client base, making it a compelling investment opportunity.
Revvity Inc. is a global life sciences company that has shifted its innovation focus to faster growing areas such as cell and gene therapy, proteins, genomics, and biologics. This strategic pivot positions Revvity to capitalize on emerging trends in the life sciences sector, enhancing its growth potential. As a recent spinoff of PerkinElmer Inc., Revvity is well-placed to leverage its legacy while expanding its research solutions to a broad client base, making it a compelling investment opportunity.
Revvity Inc. is a global life sciences company that has shifted its focus to faster growing areas such as cell and gene therapy, proteins, genomics, and biologics. This strategic pivot positions Revvity to capitalize on emerging trends in the life sciences sector, enhancing its potential for growth. As a recent spinoff of PerkinElmer Inc., Revvity is well-placed to leverage its legacy while innovating in high-demand research solutions, making it a compelling addition to the EdgePoint portfolios.
Press Release
Articles on Revvity Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
